put off talimogene laherparepvec Generic Name: talimogene laherparepvec (tal IM oh jeen la HER pa REP vek) Brand Name: Imlygic Overview Side Effects Dosage Professional Interactions More Pregnancy Warnings User Reviews Support Group Q & A What is talimogene laherparepvec? Talimogene laherparepvec is a cancer medicine that affects the actions of the body's immune system, helping the body produce an "antitumor" response. Talimogene laherparepvec is a genetically modified weak form of type 1 herpes simplex virus (the virus that causes common cold sores). Talimogene laherparepvec is used to treat a type of cancer called melanoma when it is on the skin or in the lymph glands. Talimogene laherparepvec may also be used for purposes not listed in this medication guide. Slideshow Checkpoint Inhibitors & Advanced Cancers: A Healthcare Professional's Guide What is the most important information I should know about talimogene laherparepvec? Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use. What should I discuss with my healthcare provider before receiving talimogene laherparepvec? Accidental exposure to the virus in talimogene laherparepvec may cause you to develop symptoms of herpes virus infection. However, not treating melanoma can allow the cancer to progress and spread to other parts of the body. Melanoma is difficult to treat after it progresses, and this type of cancer can be fatal. Talk to your doctor about the risks and benefits of using talimogene laherparepvec. You should not be treated with talimogene laherparepvec if you are allergic to it, or if: you have a weak immune system (caused by disease or by using certain medicine); or you are pregnant. To make sure this medicine is safe for you, tell your doctor if you have: blood cancer (leukemia); bone marrow cancer (myeloma); HIV or AIDS; an autoimmune disorder such as rheumatoid arthritis, lupus, or psoriasis; a history of cold sores or genital herpes; if you are pregnant; or if you use a steroid medication (prednisone, dexamethasone, fluticasone, or others). Tell your doctor if anyone in your household is pregnant or has a weak immune system. This medicine can harm an unborn baby or cause birth defects. Do not use if you are pregnant, and tell your doctor right away if you become pregnant. Use effective birth control to prevent pregnancy while you are using this medicine. Follow your doctor's instructions about how long to prevent pregnancy after your treatment ends. It is not known whether talimogene laherparepvec passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine. How is talimogene laherparepvec given? Talimogene laherparepvec is injected directly into a tumor on your skin, or into a lymph node under your skin. A healthcare provider will give you this injection. This medicine is usually given every 2 weeks or until your tumor is gone. The first two injections of talimogene laherparepvec are usually given 3 weeks apart. Your care providers will use special precautions to avoid getting this medicine on other areas of your body. If this medicine accidentally gets on your skin, wash it thoroughly with soap and warm water. The virus contained in talimogene laherparepvec is a weak form of the herpes simplex virus that can spread to other parts of your body. Carefully follow your doctor's instructions about taking care of the places on your body where this medicine is injected. For at least 1 week after your injection, keep the treatment area covered with an airtight and waterproof bandage. You may need to keep the treated area covered for longer than 1 week if it is draining or oozing. Change your dressing often, to keep the treated area clean. Wear latex gloves while you are cleaning the treatment area or putting on a new bandage. Place used gloves and bandages in a sealed plastic bag and throw it away in the trash. The virus in this medicine can also spread to other people you have close contact with. Avoid being near people who are sick or have infections. Avoid kissing anyone who has a mouth sore or cold sore (sometimes called a fever blister). Also avoid being near pregnant women. Call your doctor if you you have any new skin lesions or signs of lymph gland tumors after you have stopped using talimogene laherparepvec. What happens if I miss a dose? Call your doctor for instructions if you miss an appointment for your injection. What happens if I overdose? Since this medicine is given by a healthcare professional in a medical setting, an overdose is unlikely to occur. What should I avoid while receiving talimogene laherparepvec? Avoid touching or scratching the areas where this medicine was injected. The virus contained in talimogene laherparepvec can pass into body fluids (urine, feces, vomit, semen). Avoid allowing your body fluids to come into contact with your hands or other surfaces that cannot be cleaned. Always use a latex condom while having sex. Caregivers should wear rubber gloves while cleaning up a patient's body fluids, handling contaminated trash or laundry or changing diapers. Wash hands before and after removing gloves. Wash soiled clothing and linens separately from other laundry. Follow your doctor's instructions about how long you should keep using these precautions after your treatment ends. Talimogene laherparepvec side effects Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any signs that you may be developing herpes simplex virus, such as: tingling, burning, or pain (especially around your mouth or genitals); weakness or cramps in an arm or leg, sometimes with burning pain; confusion, severe drowsiness; or blisters forming on your fingers or ears, or around your mouth or genitals. Also call your doctor if you have: any skin lesion that will not heal; or redness, swelling, warmth, oozing, or skin changes where the injection was given. Common side effects may include: fever, chills, flu-like symptoms; feeling tired; nausea; or pain where the medicine was injected. This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Side Effects (complete list) Talimogene laherparepvec dosing information Usual Adult Dose for Melanoma - Metastatic: Initial Dose: -Up to 4 mL at a concentration of 10(6) [1 million] plaque-forming units (PFU) per mL by intralesional injection. -Largest lesion(s) should be injected first. -Remaining lesion(s) should be prioritized for injection based on lesion size. Second Dose: -Up to 4 mL at a concentration of 10(8) [100 million] PFU per mL by intralesional injection 3 weeks after initial treatment. -New lesions that developed since initial treatment should be injected first. -Remaining lesion(s) should be prioritized for injection based on lesion size. All Subsequent Treatments (including Reinitiation): -Up to 4 mL at a concentration of 10(8) [100 million] PFU per mL by intralesional injection 2 weeks after previous treatment. -New lesions that developed since previous treatment should be injected first. -Remaining lesion(s) should be prioritized for injection based on lesion size. Maximum Dose: The total injection volume for each treatment visit should not exceed 4 mL for all injected lesions combined. Duration of Therapy: -At each treatment visit: Lesions should be injected until maximum injection volume is reached or until all injectable lesion(s) have been treated. -Full treatment course: At least 6 months unless other treatment is required or until there are no injectable lesions to treat. Comments: The injection volume should be based on lesion size (lesions clustered together should be treated as a single lesion): -Greater than 5 cm: Up to 4 mL -Greater than 2.5 cm to 5 cm: Up to 2 mL -Greater than 1.5 cm to 2.5 cm: Up to 1 mL -Greater than 0.5 cm to 1.5 cm: Up to 0.5 mL -0.5 cm or less: Up to 0.1 mL Use: Local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. What other drugs will affect talimogene laherparepvec? Tell your doctor about all your current medicines and any you start or stop using, especially: medicine to treat herpes (acyclovir, valacyclovir, or others); or drugs that weaken the immune system (such as cancer medicine, steroids, and medicines to prevent organ transplant rejection). This list is not complete. Other drugs may interact with talimogene laherparepvec, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide. Next Side Effects Print this page Add to My Med List More about talimogene laherparepvec Side Effects During Pregnancy Dosage Information Drug Interactions Support Group En Español 0 Reviews Add your own review/rating Drug class: miscellaneous antineoplastics Consumer resources Talimogene Laherparepvec Talimogene laherparepvec Injection (Advanced Reading) Other brands: Imlygic Professional resources Talimogene Laherparepvec (AHFS Monograph) Talimogene Laherparepvec (Wolters Kluwer) Related treatment guides Melanoma Melanoma, Metastatic Where can I get more information? Your pharmacist can provide more information about talimogene laherparepvec. Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed. Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist. Copyright 1996-2012 Cerner Multum, Inc. Version: 1.01. Date modified: December 03, 2017 Last reviewed: January 04, 2016} Drug Status Rx Availability Prescription only N/A CSA Schedule Not a controlled drug Drug Class Miscellaneous antineoplastics Related Drugs Melanoma, Metastatic Opdivo , Keytruda , nivolumab , pembrolizumab , Yervoy , ipilimumab , Tafinlar , Mekinist , trametinib , dabrafenib , Proleukin , dacarbazine , More... Melanoma Opdivo , Keytruda , nivolumab , pembrolizumab , Yervoy , ipilimumab , Proleukin , dacarbazine , Intron A , Sylatron , interferon alfa-2b , aldesleukin , More... Talimogene laherparepvec Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! Help and Support Looking for answers? Ask a question or go join the talimogene laherparepvec support group to connect with others who have similar interests.} } xmas
quite a lot of talimogene laherparepvec tense
EmoticonEmoticon